Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | FAAH | O00519 | 2/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25336996 | 0.98 | TSHR (0.58) | TSHRFAAHTRPV1ALDH1A1HIF1A | |
| SCHEMBL195667 | 0.98 | TSHR (0.58) | TSHRFAAHTRPV1ALDH1A1HIF1A | |
| SCHEMBL14966102 | 0.98 | TSHR (0.58) | TSHRFAAHTRPV1ALDH1A1HIF1A | |
| SCHEMBL25231629 | 0.98 | TSHR (0.58) | TSHRFAAHTRPV1ALDH1A1HIF1A | |
| SCHEMBL4911952 | 0.98 | TSHR (0.58) | TSHRFAAHTRPV1ALDH1A1HIF1A | |
| SCHEMBL5446361 | 0.93 | — | — | |
| SCHEMBL11498365 | 0.91 | TSHR (0.61) | TSHRFAAHTRPV1ALDH1A1HIF1A | |
| SCHEMBL10441178 | 0.91 | TSHR (0.68) | TSHRFAAHTRPV1ALDH1A1MEN1 | |
| SCHEMBL8386491 | 0.88 | TSHR (0.73) | TSHRFAAHTRPV1MEN1THRB | |
| SCHEMBL15923909 | 0.88 | TSHR (0.73) | TSHRFAAHTRPV1MEN1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103421205-B | Surface modifying method and surface modified elastic body | 住友橡胶工业株式会社 | 2019-07-23 | — | — | CN | disclosed |
| WO-2014169264-A2 | NANOPARTICLE MEDIATED DELIVERY OF SIRNA | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-10-16 | — | — | WO | disclosed |
| EP-1559716-B1 | PYRAZOLONAPHTHYRIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-20100093782-A1 | Pyrazolonaphthyridine derivatives | KANAZAWA HASHIME | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093782-A1 | Pyrazolonaphthyridine derivatives | PDE3B, PDE3A, PDE4A | TSHR 1639/4885FAAH 2640/4885TRPV1 2530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.